LAVA Therapeutics’ (LVTX) “Market Perform” Rating Reiterated at Leerink Partners

Leerink Partners reaffirmed their market perform rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a report published on Thursday morning, MarketBeat.com reports. They currently have a $2.00 target price on the stock, down from their prior target price of $11.00.

Several other equities analysts also recently weighed in on LVTX. Citizens Jmp downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. JMP Securities reiterated a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a report on Wednesday. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, LAVA Therapeutics has a consensus rating of “Hold” and a consensus price target of $4.67.

LAVA Therapeutics Stock Performance

Shares of LVTX stock opened at $1.20 on Thursday. LAVA Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $6.47. The stock’s fifty day moving average is $1.70 and its two-hundred day moving average is $1.84.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pathway Financial Advisors LLC increased its stake in LAVA Therapeutics by 328.6% during the 2nd quarter. Pathway Financial Advisors LLC now owns 60,000 shares of the company’s stock worth $108,000 after buying an additional 46,000 shares during the period. XTX Topco Ltd acquired a new position in shares of LAVA Therapeutics in the second quarter worth $55,000. Finally, Virtu Financial LLC acquired a new stake in shares of LAVA Therapeutics in the third quarter valued at $32,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.